For decades, the proteins that control which genes get switched on or off inside cancer cells were considered essentially untouchable by conventional drugs — too large, too smooth-surfaced, and too deeply embedded in cellular machinery to block with small molecules. That assumption is now under serious revision, with implications for cancers that have resisted every other therapeutic approach.
This comprehensive review in Acta Pharmacologica Sinica maps the current landscape of strategies aimed at transcription factors — master regulatory proteins such as MYC, STAT3, NF-κB, and p53 — that drive tumor proliferation, survival, and treatment resistance. The authors catalogue multiple mechanistic approaches: direct binding to transcription factor DNA-binding domains, disruption of protein–protein interactions (particularly coactivator interfaces), degradation via proteolysis-targeting chimeras (PROTACs), and indirect suppression through upstream signaling inhibition. Each approach is assessed for its pharmacological strengths and the structural or biological barriers that have stalled clinical translation.
What makes this review analytically valuable is its frank engagement with why transcription factors have resisted drug development. Their intrinsically disordered regions lack stable binding pockets, and many function through vast interaction networks rather than single enzymatic steps. Yet emerging modalities — including covalent fragment-based screening, stapled peptides that mimic natural binding partners, and targeted protein degradation — are beginning to crack open interfaces previously deemed inaccessible. The field remains largely preclinical or in early-phase trials, meaning validated efficacy data in large patient populations is still sparse. Observer bias in mechanistic claims is also a limitation inherent in review-format literature. Nevertheless, the convergence of structural biology advances, AI-assisted drug design, and novel degrader chemistry positions transcription factor targeting as one of oncology's most consequential frontiers — incremental in current clinical terms, but potentially paradigm-shifting within the next decade.